Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, Huiling Feng, Xiaobao Wei, Xiaoyan Wu Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan 430071, People’s Republic of ChinaCorrespondence: Xiaoyan WuDepartment of Nephrology, Zhongnan Hospital of W...
Guardado en:
Autores principales: | Zhang Z, Ni L, Zhang L, Zha D, Hu C, Feng H, Wei X, Wu X |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6559b1e83804d1083891959214085d3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association of polymorphisms of the ADIPOQ, ADIPOR1 and ADIPOR2 genes with type 2 diabetes mellitus
por: Dmitry Sergeevich Khodyrev, et al.
Publicado: (2015) -
The CTRP3-AdipoR2 Axis Regulates the Development of Experimental Autoimmune Encephalomyelitis by Suppressing Th17 Cell Differentiation
por: Masanori A. Murayama, et al.
Publicado: (2021) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1α Signaling Pathway
por: Zhu H, et al.
Publicado: (2021) -
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
por: Ndibalema AR, et al.
Publicado: (2020)